• Subscribe
  • Magazines
  • About
  • Contact
  • Advertise
Sunday 20 July 2025
  • zh-hant 中文
  • ja 日本語
  • en English
IAG
Advertisement
  • Newsfeed
  • Mag Articles
  • Video
  • Opinion
  • Tags
  • Regional
    • Africa
    • Australia
    • Cambodia
    • China
    • CNMI
    • Europe
    • Hong Kong
    • India
    • Japan
    • Laos
    • Latin America
    • Malaysia
    • Macau
    • Nepal
    • New Zealand
    • North America
    • North Korea
    • Philippines
    • Russia
    • Singapore
    • South Korea
    • Sri Lanka
    • Thailand
    • UAE
    • Vietnam
  • Events
  • Contributors
  • SUBSCRIBE FREE
  • 中文
No Result
View All Result
IAG
  • Newsfeed
  • Mag Articles
  • Video
  • Opinion
  • Tags
  • Regional
    • Africa
    • Australia
    • Cambodia
    • China
    • CNMI
    • Europe
    • Hong Kong
    • India
    • Japan
    • Laos
    • Latin America
    • Malaysia
    • Macau
    • Nepal
    • New Zealand
    • North America
    • North Korea
    • Philippines
    • Russia
    • Singapore
    • South Korea
    • Sri Lanka
    • Thailand
    • UAE
    • Vietnam
  • Events
  • Contributors
  • SUBSCRIBE FREE
  • 中文
No Result
View All Result
IAG
No Result
View All Result

MUST: Funding equal to LESS THAN ONE SINGLE DAY of Macau’s 2019 casino GGR would be enough to develop, produce 30 million doses of COVID-19 vaccine candidate

Andrew W Scott and Ben Blaschke by Andrew W Scott and Ben Blaschke
Tue 4 Aug 2020 at 17:43
MUST: Funding equal to LESS THAN ONE SINGLE DAY of Macau’s 2019 casino GGR would be enough to develop, produce 30 million doses of COVID-19 vaccine candidate

Professor Zhang Kang explains how the team’s vaccine attacks the Receptor Binding Domain (RBD) of the virus protein rather than the whole spike.

83
SHARES
1.3k
VIEWS
Print Friendly, PDF & Email

Scientists responsible for developing what they describe as a hugely promising COVID-19 vaccine candidate say they can complete human trials and produce 30 million doses by January 2021 on less than a single day’s worth of Macau 2019 casino revenue.

The revelations came at a press conference at the Faculty of Medicine at Macau University of Science and Technology (MUST) on Tuesday. The press conference was led by Professor Zhang Kang in Macau, and Professor Manson Fok, Dean of the Faculty, who appeared from Hong Kong by video.

The vaccine, announced last week by a team comprising researchers from MUST, in collaboration with Hong Kong Polytechnic University (PolyU), is seen as a leading candidate for mass production after what the researchers describe as exceptional results during early clinical trials. In particular, it induced a “potent functional antibody response” in immunized mice, rabbits and monkeys with those antibodies subsequently neutralizing the virus during laboratory studies by effectively blocking it from binding with cells in the host.

According to key scientists involved, the candidate vaccine is now ready to enter Phase II and Phase III trials which, if all goes well, could see the first 30 million doses manufactured and ready for distribution by late January.

However, at the press conference, it was revealed the project was at risk of stalling over a shortfall in funding. Speaking of the world’s largest casino hub, Professor Fok estimated HK$600 million (US$77 million), equivalent to 77% of one day of Macau casino revenue based on 2019 GGR, or just two days’ worth of gaming taxes collected by the Macau SAR Government, would be needed to develop and produce 30 million doses of the vaccine.

Journalists at Tuesday’s press conference.

The team revealed it had been knocked back in February after applying to the Macau government for funding of just MOP$500,000 (US$62,500), with Professor Fok indicating the government had not been convinced at the time that development of a vaccine was a realistic goal.

According to the MUST team, the cost of the collaborative research, which has involved more than 100 scientists from Macau, Hong Kong and mainland China, is already in the “tens of millions of US dollars” – all of it sourced from the internal resources of eight institutions involved.

But the team is also adamant their vaccine ranks among the most effective, perhaps even the most effective, of the more than 150 vaccine candidates currently being studied globally.

“From a conceptual standpoint, we think this will be a highly effective vaccine with a very low level of side effects,” said Professor Zhang, one of the team’s leaders.

According to Zhang, the team’s vaccine stands out from most others because it only attacks the Receptor Binding Domain (RBD) of the protein rather than the whole protein spike, therefore creating more effective antibodies.

The vaccine is also a standout because it utilizes recombinant DNA, such as that already used in the HPV vaccine widely used to combat various forms of cancer and genital warts. The technology is already readily available and used in manufacturing facilities around the world.

L to R: Dean Fok appearing by video alongside Professor Zhang Kang.

Zhang said the team initiated development of its vaccine shortly after Chinese New Year, with Phase I testing showing no side effects. They are also encouraged by the fact that the vaccine requires administration of an extremely small dose – around 20 micrograms or 1/10th the size of a sesame seed.

Notably, Zhang says the vaccine should even be able to treat those already sick with COVID-19.

The team is now waiting to progress to the next step, Zhang said, where it plans to run Phase II and Phase III trials in humans concurrently to expedite the process.

“We are very confident from our results in the animal studies of its worth,” he said.

Fok added, “Normally human trials to deployment is one-and-a-half to two years,” but pointed to the fact that COVID-19 is not a normal situation. “So far the vaccine has shown strong antibody response, no complications, a significant half-life and it will be very cost effective.”

Macau University of Science and Technology.

Fok did, however, note the vaccine could not be produced locally due to the absence of a vaccine facility in Macau, and a lack of testing capacity in mainland China due to a number of other candidate vaccines being tested. Instead, the MUST team has agreed to conduct a pilot manufacturing program with a partner in Taiwan, which they say has the capability to produce at least 30 million doses in a matter of weeks.

As previously reported by IAG, 8 million of those would be reserved for the people of Macau and Hong Kong. The team, Fok claimed, wants to “produce a vaccine for all of humanity.

“This is a global problem and needs a global solution,” he said.

RelatedPosts

Hong Kong Jockey Club says racing turnover grew 3% to US$17.7 billion in 2024/25 season

Hong Kong Jockey Club says racing turnover grew 3% to US$17.7 billion in 2024/25 season

Sun 20 Jul 2025 at 07:31
SJM and Macau police hold large-scale drill simulating casino robbery

SJM and Macau police hold large-scale drill simulating casino robbery

Thu 17 Jul 2025 at 12:37
Macau GGR comes in at MOP$18.9 billion in April, up 1.7% year-on-year

Macau VIP baccarat up almost 23% year-on-year to US$2 billion in June 2025 quarter

Thu 17 Jul 2025 at 07:04
Macau visitor numbers back to 95% of 2019 levels in first half of 2025

Macau visitor numbers back to 95% of 2019 levels in first half of 2025

Wed 16 Jul 2025 at 14:47
Load More
Tags: Chinacovid-19Hong KongHong Kong Polytechnic UniversityMacauMacau University of Science and TechnologyMUSTProfessor Manson FokProfessor Zhang KangVaccination
Share53Share4
Andrew W Scott and Ben Blaschke

Andrew W Scott and Ben Blaschke

A former sports journalist in Sydney, Australia, Ben has been Managing Editor of Inside Asian Gaming since early 2016. He played a leading role in developing and launching IAG Breakfast Briefing in April 2017 and oversees as well as being a key contributor to all of IAG’s editorial pursuits.

Born in Australia, Andrew is a gaming industry expert and media publisher, commentator and journalist who moved to Hong Kong in 2005 and then Macau in 2009, when he founded O MEDIA, one of Macau’s largest media companies and parent company of Inside Asian Gaming.

Current Issue

Editorial – An inconvenient truth

Editorial – An inconvenient truth

by Ben Blaschke
Fri 27 Jun 2025 at 15:21

It’s understandable that political observers, academics and members of the public in greenfield jurisdictions would express caution around the legalization...

Light & Wonder’s Siobhan Lane

Light & Wonder’s Siobhan Lane

by Ben Blaschke
Fri 27 Jun 2025 at 15:19

Siobhan Lane, Light & Wonder’s highly experienced CEO of Gaming, speaks to Inside Asian Gaming about the company’s ongoing transformation...

Honesty is the best policy

Honesty is the best policy

by Ben Blaschke
Fri 27 Jun 2025 at 14:13

The Thailand Entertainment Complex Roundtable brought industry stakeholders, politicians and supporters of the government’s Entertainment Complex Bill face to face...

Sri Lanka’s casino industry

Sri Lanka’s casino industry

by Shaun McCamley
Fri 27 Jun 2025 at 13:36

Industry veteran Shaun McCamley delves into the complex history of Sri Lanka’s casino industry at a time when the country...

Evolution Asia
Your browser does not support HTML5 video.
Aristocrat
GLI
Nustar
SABA
Mindslot
Solaire
Hann
Tecnet
NWR
Jumbo
568Win

Related Posts

Light & Wonder sets new US$2 billion Adjusted EBITDA target for 2028

Light & Wonder granted Gaming-Related Vendor License in UAE

by Newsdesk
Sun 20 Jul 2025 at 07:33

Light & Wonder, Inc said Friday that it has been granted a gaming-related vendor license by the General Commercial Gaming Regulatory Authority (GCGRA) of the United Arab Emirates, making it the 13th industry supplier to be granted a gaming-related vendor...

Hong Kong Jockey Club says racing turnover grew 3% to US$17.7 billion in 2024/25 season

Hong Kong Jockey Club says racing turnover grew 3% to US$17.7 billion in 2024/25 season

by Newsdesk
Sun 20 Jul 2025 at 07:31

The Hong Kong Jockey Club has reported a return to growth for the local racing industry with total racing wagering turnover in the 2024/25 Hong Kong season rising 3.0% to HK$138.85 billion (US$17.7 billion). This compares to a 4.5% decline...

Early Mover

Philippines SEC gives approval to Hann’s US$200 million IPO

by Newsdesk
Sun 20 Jul 2025 at 07:09

The Philippines’ Securities and Exchange Commission (SEC) has approved the initial public offering (IPO) of Hann Holdings Inc – the holding company of Clark’s Hann Casino Resort. In a statement issued Friday, the SEC said it had “considered favorably” Hann’s...

Star to open AU$3.6 billion Queen’s Wharf Brisbane development on 29 August

Star’s Hong Kong partners said to be eying Crown Resorts to run casino at Queen’s Wharf Brisbane if takeover talks succeed

by Ben Blaschke
Fri 18 Jul 2025 at 11:11

Star Entertainment Group’s Hong Kong partners are reportedly looking to replace Star with its local rival Crown Resorts as operator of the casino at Queen’s Wharf Brisbane should the partners complete a deal to acquire Star’s 50% stake in the...



IAG

© 2005-2024
Inside Asian Gaming.
All rights reserved.

  • SUBSCRIBE FREE
  • NEWSFEED
  • MAG ARTICLES
  • VIDEO
  • OPINION
  • TAGS
  • REGIONAL
  • EVENTS
  • CONSULTING
  • CONTRIBUTORS
  • MAGAZINES
  • ABOUT
  • CONTACT
  • ADVERTISE
  • 中文

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

No Result
View All Result
  • 中文
  • Subscribe
  • Newsfeed
  • Mag Articles
  • Video
  • Opinion
  • Tags
  • Regional
  • Events
  • Contributors
  • Magazines
  • Advertise
  • Contact
  • About
  • Home for G2E Asia

© 2005-2024
Inside Asian Gaming.
All rights reserved.

  • 中文
  • English